We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

A PharmaSphere Inc. subsidiary didn’t mislead the US Patent and Trademark Office to obtain the patent at the center of an ...

Fresenius Medical Care ( ($FMS) ) has shared an announcement. On April 1, 2025, Fresenius Medical Care successfully placed bonds totaling €1.1 ...

Fresenius, Danone and Proximus benchmarks shake off tariff turmoil ◆ Range of new issue concessions needed ◆ High orderbook attrition for those pushing hard on spread ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss ...

Fresenius SE FRE0.03%increase; green up pointing triangle said it raised around 1.1 billion euros ($1.15 billion) after selling part of its Fresenius Medical Care FME 0.88%increase; green up ...

On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Fresenius SE raised close to €1.1 billion ($1.2 billion) in a sale of shares in Fresenius Medical Care AG as well as exchangeable bonds linked to the dialysis firm, as it looks to cut debt and ...

JD.com, Universal Health Services, Fresenius Medical Care and Qifu Technology are part of the Zacks Screen of the Week article.

In a report released today, Graham Doyle from UBS maintained a Buy rating on Fresenius SE & Co. KGaA (0OO9 – Research Report), with a price ...